MedTrace Logo

Clinical Pharmacology Study of AZD7295 in Healthy Subjects

NCT00906256 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2010-02-12

No results posted yet for this study

Summary

The purpose of this study is to determine the pharmacokinetic profile of oral doses of AZD7295 capsules in healthy subjects, and also to assess the effects of food as well as safety and tolerability.

Conditions

  • Healthy

Interventions

DRUG

AZD7295

Capsules 260mg, 455mg, 650mg (single doses), 650mg q12h, 650mg q8h.

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Arrow Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00906256 on ClinicalTrials.gov